A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin

Trial Profile

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs RG 7697 (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 10 Jun 2017 Biomarkers information updated
    • 31 Dec 2015 Status changed from active, no longer recruiting to completed according ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top